Full-Time

Head of Market Access

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$284k - $355kAnnually

Expert

San Carlos, CA, USA

In-office presence required at least 3 days per week.

Category
Strategy Development
Business Development
Business & Strategy
Requirements
  • Minimum of fifteen (15) years of biopharmaceutical market access experience, including payer, reimbursement, pricing & contracting, field team leadership, and established relationships with several key national and regional payers.
  • Strong understanding of healthcare policy, payer dynamics, healthcare system, and regulatory landscape.
  • Deep understanding of and compliance with the OIG and FDA regulations.
Responsibilities
  • Develop RevMed’s market access strategy and tactics to ensure successful initial product launches and maximization of lifecycle value.
  • Design and lead execution of access, reimbursement & pricing plans.
  • Provide strategic leadership and direction for payer access, coverage, reimbursement, patient support services, pricing and distribution, list and net pricing, and contracting across all payer types.
  • Design and drive the strategic plan for market access capabilities within the US (and globally as needed) including strategic account management, patient access programs, trade and distribution, contracting, and health economics and pricing.
  • Develop US pricing recommendations to ensure alignment as it relates to contracting, rebating, price adjustments, best price, and other related elements.
  • Work collaboratively to recommend and execute a US managed care strategy for payer and key channels, including commercial insurers, Pharmacy Benefit Managers (PBMs), Integrated Health Networks (IHN), State Medicaid, Medicare, and Federal VA/DoD channels.
  • Proactively meet with senior leadership at key U.S. payers to identify opportunities for broader collaboration and partnership, including both regional and national health plans.
  • Collaborate with Marketing in the development of the product value proposition and other resources for payer account managers, and pull-through communications and resources for the US field team(s).
  • Oversee the design and execution of the patient support services hub.
  • Build and lead a high-functioning Market Access team and infrastructure to ensure optimal access solutions for patients and providers, including the appropriate field-based customer team to ensure optimal access.
  • In partnership with Medical Affairs and Clinical Development, ensure clinical research incorporates HEOR needs, and be responsible for the health economic and broader value assessment. Oversee the development of budget impact and cost-effectiveness models.
Desired Qualifications
  • BS/BA degree; master’s degree or higher preferred.
  • Broad commercial experience including oncology product launches.
  • Proven leadership experience building from the ground up and leading high-performing teams.
  • Excellent communication and negotiation skills.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to concentrate their research and development efforts in this niche area. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity